Literature DB >> 22983646

Sequential monitoring of serum IL-6, TNF-α, and IFN-γ levels in a CAEBV patient treated by plasma exchange and immunochemotherapy.

Ayako Arai1, Ayako Nogami, Ken-Ichi Imadome, Morito Kurata, Naomi Murakami, Shigeyoshi Fujiwara, Osamu Miura.   

Abstract

We report the case of a female patient with chronic active Epstein-Barr virus infection (CAEBV) accompanied by hemophagocytic syndrome (HPS). On admission, she presented with severe liver dysfunction and disseminated intravascular coagulation with elevation of serum IL-6, TNF-α, and IFN-γ levels. Plasma exchange (PE) followed by immunochemotherapy with prednisolone, cyclosporine A, and VP16 was performed. PE decreased serum cytokine levels dramatically and improved liver function. Following immunochemotherapy, CAEBV became inactive. Four months after discharge, however, CAEBV relapsed with HPS, and serum cytokine levels were extremely elevated again. There was no response to immunochemotherapy, and the patient died 1 day after admission. We examined the cytokines in five additional untreated-CAEBV patients and determined that they were elevated above the normal level in all patients. These results suggest that inflammatory cytokines may have roles in the development of CAEBV, and that their depletion can be an effective treatment for this disease.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22983646     DOI: 10.1007/s12185-012-1170-2

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  20 in total

1.  Late Epstein-Barr virus infection of a hepatosplenic gamma delta T-cell lymphoma arising in a kidney transplant recipient.

Authors:  S Roncella; G Cutrona; M Truini; I Airoldi; A Pezzolo; A Valetto; D Di Martino; P Dadati; A De Rossi; M Ulivi; I Fontana; A Nocera; U Valente; M Ferrarini; V Pistoia
Journal:  Haematologica       Date:  2000-03       Impact factor: 9.941

2.  HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis.

Authors:  Jan-Inge Henter; Annacarin Horne; Maurizio Aricó; R Maarten Egeler; Alexandra H Filipovich; Shinsaku Imashuku; Stephan Ladisch; Ken McClain; David Webb; Jacek Winiarski; Gritta Janka
Journal:  Pediatr Blood Cancer       Date:  2007-02       Impact factor: 3.167

3.  Clinical features of adult-onset chronic active Epstein-Barr virus infection: a retrospective analysis.

Authors:  Ayako Arai; Ken-Ichi Imadome; Yuko Watanabe; Mayumi Yoshimori; Takatoshi Koyama; Takeharu Kawaguchi; Chiaki Nakaseko; Shigeyoshi Fujiwara; Osamu Miura
Journal:  Int J Hematol       Date:  2011-04-14       Impact factor: 2.490

Review 4.  Pathogenesis of chronic active Epstein-Barr virus infection: is this an infectious disease, lymphoproliferative disorder, or immunodeficiency?

Authors:  Hiroshi Kimura
Journal:  Rev Med Virol       Date:  2006 Jul-Aug       Impact factor: 6.989

5.  Success with infliximab in treating refractory hemophagocytic lymphohistiocytosis.

Authors:  Tomoko Henzan; Koji Nagafuji; Hiroshi Tsukamoto; Toshihiro Miyamoto; Hisashi Gondo; Shinsaku Imashuku; Mine Harada
Journal:  Am J Hematol       Date:  2006-01       Impact factor: 10.047

Review 6.  Proposed guidelines for diagnosing chronic active Epstein-Barr virus infection.

Authors:  Motohiko Okano; Keisei Kawa; Hiroshi Kimura; Akihiro Yachie; Hiroshi Wakiguchi; Akihiko Maeda; Shosuke Imai; Shouichi Ohga; Hirokazu Kanegane; Shigeru Tsuchiya; Tomohiro Morio; Masaaki Mori; Shumpei Yokota; Shinsaku Imashuku
Journal:  Am J Hematol       Date:  2005-09       Impact factor: 10.047

7.  Excellent outcome of allogeneic hematopoietic SCT with reduced-intensity conditioning for the treatment of chronic active EBV infection.

Authors:  K Kawa; A Sawada; M Sato; T Okamura; N Sakata; O Kondo; T Kimoto; K Yamada; S Tokimasa; M Yasui; M Inoue
Journal:  Bone Marrow Transplant       Date:  2010-05-24       Impact factor: 5.483

8.  [An autopsied case of chronic active Epstein-Barr virus infection complicated in systemic lupus erythematosus and antiphospholipid antibody syndrome].

Authors:  Jun Ogawa; Ryuji Koike; Takahiko Sugihara; Hiroyuki Hagiyama; Junko Nishio; Hitoshi Kohsaka; Tetsuo Kubota; Hiroshi Kawachi; Ichiro Kasahara; Nobuyuki Miyasaka
Journal:  Nihon Rinsho Meneki Gakkai Kaishi       Date:  2002-12

9.  Co-existence of acute myeloid leukemia with multilineage dysplasia and Epstein-Barr virus-associated T-cell lymphoproliferative disorder in a patient with rheumatoid arthritis: a case report.

Authors:  Michihide Tokuhira; Kyoko Hanzawa; Reiko Watanabe; Yasunobu Sekiguchi; Tomoe Nemoto; Yasuo Toyozumi; Jun-ichi Tamaru; Shinji Itoyama; Katsuya Suzuki; Hideto Kameda; Shigehisa Mori; Masahiro Kizaki
Journal:  J Hematol Oncol       Date:  2009-06-30       Impact factor: 17.388

10.  Quantitative analysis of Epstein-Barr virus load by using a real-time PCR assay.

Authors:  H Kimura; M Morita; Y Yabuta; K Kuzushima; K Kato; S Kojima; T Matsuyama; T Morishima
Journal:  J Clin Microbiol       Date:  1999-01       Impact factor: 5.948

View more
  9 in total

1.  Hematopoietic stem cell transplantation for adults with EBV-positive T- or NK-cell lymphoproliferative disorders: efficacy and predictive markers.

Authors:  A Arai; C Sakashita; C Hirose; K-I Imadome; M Yamamoto; M Jinta; S Fujiwara; M Tomita; N Shimizu; T Morio; O Miura
Journal:  Bone Marrow Transplant       Date:  2016-02-22       Impact factor: 5.483

2.  Retrospective analysis of plasma exchange combined with glucocorticosteroids for the treatment of systemic lupus erythematosus-related acute pancreatitis in central China.

Authors:  Yi-Kai Yu; Fei Yu; Cong Ye; Yu-Jie Dai; Xiao-Wei Huang; Shao-Xian Hu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-07-28

3.  Infectious mononucleosis accompanied by clonal proliferation of EBV-infected cells and infection of CD8-positive cells.

Authors:  Ayako Arai; Takeshi Yamaguchi; Honami Komatsu; Ken-Ichi Imadome; Morito Kurata; Kaoru Nagata; Osamu Miura
Journal:  Int J Hematol       Date:  2014-03-19       Impact factor: 2.490

4.  Antineoplastic and anti-inflammatory effects of bortezomib on systemic chronic active EBV infection.

Authors:  Mayumi Yoshimori; Haruna Shibayama; Ken-Ichi Imadome; Fuyuko Kawano; Ayaka Ohashi; Miwako Nishio; Norio Shimizu; Morito Kurata; Shigeyoshi Fujiwara; Ayako Arai
Journal:  Blood Adv       Date:  2021-04-13

5.  Clinicopathologic findings of chronic active Epstein-Barr virus infection in adults: A single-center retrospective study in China.

Authors:  Jing Lin; Haicong Wu; Lei Gu; Xia Wu; Miaofang Su; Haiyan Lin; Bang Liu; Jiaolong Zheng; Xuan Mei; Dongliang Li
Journal:  Clin Exp Med       Date:  2021-02-26       Impact factor: 3.984

6.  EBV induces persistent NF-κB activation and contributes to survival of EBV-positive neoplastic T- or NK-cells.

Authors:  Honami Takada; Ken-Ichi Imadome; Haruna Shibayama; Mayumi Yoshimori; Ludan Wang; Yasunori Saitoh; Shin Uota; Shoji Yamaoka; Takatoshi Koyama; Norio Shimizu; Kouhei Yamamoto; Shigeyoshi Fujiwara; Osamu Miura; Ayako Arai
Journal:  PLoS One       Date:  2017-03-27       Impact factor: 3.240

7.  STAT3 is constitutively activated in chronic active Epstein-Barr virus infection and can be a therapeutic target.

Authors:  Erika Onozawa; Haruna Shibayama; Honami Takada; Ken-Ichi Imadome; Sho Aoki; Mayumi Yoshimori; Norio Shimizu; Shigeyoshi Fujiwara; Takatoshi Koyama; Osamu Miura; Ayako Arai
Journal:  Oncotarget       Date:  2018-07-24

8.  The Plasma Level of Interleukin-1β Can Be a Biomarker of Angiopathy in Systemic Chronic Active Epstein-Barr Virus Infection.

Authors:  Ayaka Ohashi; Yu Uemura; Mayumi Yoshimori; Naomi Wada; Ken-Ichi Imadome; Kazuo Yudo; Takatoshi Koyama; Norio Shimizu; Miwako Nishio; Ayako Arai
Journal:  Front Microbiol       Date:  2022-04-06       Impact factor: 6.064

Review 9.  Hemophagocytic lymphohistiocytosis in an adult kidney transplant recipient successfully treated by plasmapheresis: A case report and review of the literature.

Authors:  Christian Nusshag; Christian Morath; Martin Zeier; Markus A Weigand; Uta Merle; Thorsten Brenner
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.